Desoximetasone

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

• Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

• Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.contraindicated

Apply a thin film of desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% to the affected skin areas twice daily. Rub in gently.

Keep out of reach of children.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies the incidence of adverse reactions were low (0.8%) for desoximetasone cream USP, 0.25%, and included burning, folliculitis, and folliculo-pustular lesions. The incidence of adverse reactions were also 0.8% for desoximetasone cream USP, 0.05% and included pruritus, erythema, vesiculation, and burning sensation. The incidence of adverse reactions for desoximetasone gel USP, 0.05% was 0.3% with one subject reporting stinging and burning at the site of application.

Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream USP, 0.25% and 15 to 150 times the human dose of desoximetasone cream USP, 0.05%, or desoximetasone gel USP, 0.05%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Metabolism

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

• Jan 17, 1985NDANDA018594Taro
• Nov 29, 1990ANDAANDA073193Taro
• Nov 30, 1990ANDAANDA073210Taro
• Jun 7, 1996ANDAANDA074286Taro
• Jul 14, 1998ANDAANDA074904Taro
• Jul 1, 2003ANDAANDA076510Padagis Israel
• Apr 11, 2013NDANDA204141Sun Pharma Canada
• Sep 20, 2013ANDAANDA202838Glenmark Pharms Ltd

1. 1Drug Ineffective9,88453%
2. 2Pain8,92548%
3. 3Fatigue8,78347%
4. 4Alopecia8,23344%
5. 5Rheumatoid Arthritis8,18944%
6. 6Systemic Lupus Erythematosus8,09544%
7. 7Pemphigus7,85642%
8. 8Abdominal Discomfort7,79842%
9. 9Glossodynia7,63141%
10. 10Swelling7,13238%
11. 11Hand Deformity6,93437%
12. 12Rash6,83437%
13. 13Arthropathy6,77437%
14. 14Drug Intolerance6,65336%
15. 15Wound6,46635%

Recent PubMed references pinned to Desoximetasone as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Cushing's syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes.
  International journal of obesity (2005) · 2024 · Hepsen S, Gul U, Bostan H, et al.
  PMID 39122909DOI 10.1038/s41366-024-01598-0
• A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling.
  International journal of molecular sciences · 2023 · Matharoo NS, Garimella HT, German C, et al.
  PMID 37894801DOI 10.3390/ijms242015118
• Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone.
  International journal of molecular sciences · 2021 · Shah P, Goodyear B, Dholaria N, et al.
  PMID 33546426DOI 10.3390/ijms22041535
• Adherence to topical treatment can improve treatment-resistant moderate psoriasis.
  Cutis · 2020 · Okwundu N, Cardwell LA, Cline AE, et al.
  PMID 32186523
• A Diffuse Papular Rash in an Adult.
  The American journal of medicine · 2020 · Swali R, Wiggins C, Tyring SK, et al.
  PMID 32004505DOI 10.1016/j.amjmed.2019.12.036
• Is topical treatment effective for psoriasis in patients who failed topical treatment?
  The Journal of dermatological treatment · 2021 · Okwundu N, Cardwell L, Cline A, et al.
  PMID 31132897DOI 10.1080/09546634.2019.1617830
• Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema.
  Dermatologic therapy · 2019 · Juntongjin P, Pongprasert R
  PMID 31070845DOI 10.1111/dth.12956
• Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray.
  Journal of cutaneous medicine and surgery · 2019 · Hogue L, Cardwell LA, Roach C, et al.
  PMID 30556414DOI 10.1177/1203475418818082

The 10 most recently updated of 10 ClinicalTrials.gov registrations naming Desoximetasone as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray
  Completed · Phase 4 · Interventional · 20 enrolled · Psoriasis Treatment Center of Central New Jersey
  NCT02985736updated 2024-04-09
• Topical Psoriasis Study for Patients Receiving Biologic Therapy
  Completed · Phase 4 · Interventional · 20 enrolled · Psoriasis Treatment Center of Central New Jersey
  NCT02983981updated 2024-03-20
• Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
  Completed · Phase 4 · Interventional · 129 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT02340169updated 2023-03-28
• Evaluating Treatment Resistant Dermatitis TaroIIR
  Completed · Phase 4 · Interventional · 24 enrolled · Wake Forest University Health Sciences
  NCT03050294updated 2020-05-20
• Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
  Completed · Phase 3 · Interventional · 124 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT02595073updated 2018-12-07
• Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
  Completed · Phase 3 · Interventional · 120 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT01206387updated 2017-06-05
• Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis
  Unknown · Phase 3 · Interventional · 105 enrolled · Siriraj Hospital
  NCT02749656updated 2017-05-01
• Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
  Completed · Phase 2 · Interventional · 151 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT01018134updated 2014-08-05
• Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
  Completed · Phase 3 · Interventional · 120 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT01206660updated 2014-07-03
• Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
  Completed · Phase 2 · Interventional · 24 enrolled · Sun Pharmaceutical Industries, Inc.
  NCT01043393updated 2014-06-02

Frequently asked questions

How does Desoximetasone work?

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

What is Desoximetasone used for?

According to FDA labeling, Desoximetasone carries indications including: Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Desoximetasone?

Desoximetasone is classified as Corticosteroids, potent (group III), Corticosteroids, potent, other combinations, Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Antipruritic Activity, Decreased Immunologically Active Molecule Activity, Decreased Protein Synthesis, Vasoconstriction.

What are the brand names for Desoximetasone?

Desoximetasone is marketed under brand names including Topicort.

What are the contraindications for Desoximetasone?

Desoximetasone labeling lists contraindications including: Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.. Always consult the full prescribing information and a clinician.